HA155
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530383

CAS#: 1229652-22-5

Description: HA155, also known as Autotaxin Inhibitor IV, is a boronic acid-based compound that inhibits autotaxin (IC50 = 5.7 nM) by selectively binding to its catalytic threonine.


Price and Availability

Size
Price

5mg
USD 230
Size
Price

10mg
USD 390
Size
Price

25mg
USD 760

HA155, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 530383
Name: HA155
CAS#: 1229652-22-5
Chemical Formula: C24H19BFNO5S
Exact Mass: 463.1061
Molecular Weight: 463.2864
Elemental Analysis: C, 62.22; H, 4.13; B, 2.33; F, 4.10; N, 3.02; O, 17.27; S, 6.92


Synonym: HA155; HA-155; HA 155. Autotaxin Inhibitor IV.

IUPAC/Chemical Name: B-[4-[[4-[[3-[(4-fluorophenyl)methyl]-2,4-dioxo-5-thiazolidinylidene]methyl]phenoxy]methyl]phenyl]-boronic acid

InChi Key: BRWUZCBSWABPMR-XKZIYDEJSA-N

InChi Code: InChI=1S/C24H19BFNO5S/c26-20-9-3-17(4-10-20)14-27-23(28)22(33-24(27)29)13-16-5-11-21(12-6-16)32-15-18-1-7-19(8-2-18)25(30)31/h1-13,30-31H,14-15H2/b22-13-

SMILES Code: OB(C1=CC=C(COC2=CC=C(/C=C(SC(N3CC4=CC=C(F)C=C4)=O)/C3=O)C=C2)C=C1)O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Katsamakas S, Papadopoulos AG, Hadjipavlou-Litina D. Boronic Acid Group: A
Cumbersome False Negative Case in the Process of Drug Design. Molecules. 2016 Sep
7;21(9). pii: E1185. doi: 10.3390/molecules21091185. PubMed PMID: 27617984.

2: Albers HM, Hendrickx LJ, van Tol RJ, Hausmann J, Perrakis A, Ovaa H.
Structure-based design of novel boronic acid-based inhibitors of autotaxin. J Med
Chem. 2011 Jul 14;54(13):4619-26. doi: 10.1021/jm200310q. PubMed PMID: 21615078;
PubMed Central PMCID: PMC3131786.